Rahul Banerjee, Assistant Professor at the Fred Hutchinson Cancer Center shared on X:
“Best myeloma study I’ve ever put patients on
- Commercial lead-in allowed
- MRD neg: ASCT deferral vs not
- MRD pos: tec-dara (à la TEC-4) vs standard dara-len
- Sustained MRD-neg? Stop all treatment!
Thanks Luciano J Costa for leading us all – looking forward to results!”
You may also find this interesting:
Myeloma Paper of the Day, September 21st, Suggested by Robert Orlowski
